Sickle Cell Disease – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of sickle cell disease (SCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets in North America and Europe (the United States, France, Germany, Italy, Spain, and the United Kingdom). We report the diagnosed prevalence of SCD for each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of 10 years.
Clarivate Epidemiology’s SCD forecast will answer the following questions:
- Of all people diagnosed with SCD, how many in each of the pharmaceutical markets under study are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SCD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each year, Clarivate Epidemiology provides at least 10 years of data for the following SCD subpopulations:
- Diagnosed prevalent cases by disease subgroup.
- Diagnosed prevalent cases by treatment status.
Note: Coverage may vary by country.
Table of contents
- Sickle Cell Disease - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Prevalence of Sickle Cell Disease per 1,000 People of All Ages in 2021 and 2031
- Prevalence of Sickle Cell Disease per 1,000 People of All Ages in 2021 and 2031
- Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Sickle Cell Disease Over the Next 10 Years
- Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Sickle Cell Disease Over the Next 10 Years
- Analysis of the Prevalent Cases of Sickle Cell Disease in 2021 by Disease Subgroup
- Analysis of the Prevalent Cases of Sickle Cell Disease in 2021 by Disease Subgroup
- Analysis of the Diagnosed Prevalent Cases of Sickle Cell Disease in 2021 by Drug-Treated Status
- Analysis of the Diagnosed Prevalent Cases of Sickle Cell Disease in 2021 by Drug-Treated Status
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Latashree Goswami, M.P.H., is an associate epidemiologist at Clarivate. Her areas of interest include oncology and autoimmune disorders. She holds an M.P.H. from the Indian Institute of Public Health, where she specialized in health economics, financing, and policy, and a B.D.S. from India’s ITS Dental College.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.